India, April 10 -- image credit- shutterstock

Biocon Biologics Ltd(BBL), a subsidiary of Bengaluru-based Biocon Ltd has announced that the US Food and Drug Administration (US FDA) has approved Jobevne (bevacizumab-nwgd), a biosimilar Bevacizumab for intravenous use.

Jobevne, a recombinant humanised monoclonal antibody used to treat several different types of cancer, is a biosimilar to the reference product Avastin (bevacizumab). Jobevne is a vascular endothelial growth factor (VEGF) inhibitor that binds with VEGF and blocks the interaction with its receptors to prevent angiogenesis, combating cancer by restricting blood supply to the tumor.

The approval ofJobevne expands Biocon Biologics' biosimilar oncology portfolio in the United Sta...